Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy

Dronedarone, a new Class III antiarrhythmic agent, has now been approved by the US Food and Drug Administration for use in patients with atrial fibrillation or atrial flutter. Approval came in March 2009 due to the positive results of the ATHENA trial showing significant reductions in all-cause mort...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolbrette, Deborah, Gonzalez, Mario, Samii, Soraya, Banchs, Javier, Penny-Peterson, Erica, Naccarelli, Gerald
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922313/
https://www.ncbi.nlm.nih.gov/pubmed/20730068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922313/
https://www.ncbi.nlm.nih.gov/pubmed/20730068

Ejemplares similares